I25.1
Conditions
Interventions
Group 1: Intervention group
Nicotinamide 500mg (vitamin B3 in capsules, 250mg per capsule, taken per os, 2 capsules daily over an observation period of 8 weeks)
Group 2: Control group
Placebo (cellu
Sponsors
Medizinische Universität Graz
Eligibility
Sex/Gender
All
Age
19 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Written declaration of consent from the study participants to participate in the study after detailed explanation of the nature, significance, risks and scope of the study - Systolic blood pressure >110mmHg - Outpatient cardiac rehabilitation that has been ongoing for > 3 months - Stable drug treatment of the underlying cardiac disease
Exclusion criteria
Exclusion criteria: - Higher grade supraventricular or ventricular arrhythmias - Renal insufficiency with GFR < 45ml/min - Insulin dependent diabetes mellitus - Expected life expectancy < 1 year - Current participation in another clinical trial - Taking vitamin supplements containing niacin/vitamin B3
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantification of Nicotinamide Adenine Dinucleotide (NAD+) concentration in blood The quantification is done using ultra high performance liquid chromatography coupled with mass spectrometry (UHPLC-MS) at baseline and after 8 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| NAD metabolomes in plasma and PBMCs Spiro ergometry: maximum exhaustion level in % of target; maximum exhaustion level in watts; heart rate increase during exercise; maximum heart rate during exercise; VO2max; anaerobic threshold Electrocardiography: Standard analyses Autophagy in PBMCs Immune cell profiles Plasma cytokines | — |
Countries
Austria
Contacts
Public ContactDirk von Lewinski
Medizinische Universität Grz
Outcome results
None listed